Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction

Transplant International

Volumn 17, Issue 9, 2004, Pages 518-524

  Koch, Robert O ^a   Graziadei, Ivo W ^a   Schulz, Frank ^a   Nachbaur, Karin ^a   Königsrainer, Alfred ^a   Margreiter, Raimund ^a   Vogel, Wolfgang ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Calcineurin inhibitor; Immunosuppression; Mycophenolate mofetil; Nephrotoxicity

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HAIR LOSS; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RECIPIENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; CALCINEURIN; CREATININE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 9944252971     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.tb00481.x     Document Type: Article

References (18)

1. Williams JW, Vera SR, Peters TG, Van Voorst S. Survival following hepatic transplantation in the cyclosporine era. Am Surg 1986; 52:291.
2. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65:180.
3. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The US Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331:1110.
4. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66:59.
5. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58:170.
6. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7:161.
7. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321.
8. Gavlik A, Demirbas A, Tsaroucha A, Webb MG, Nery JR, Khan MF, et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. Transplant Proc 1997; 29:2971.
9. Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67:707.
10. Herrero JI, Quiroga JF, Sangro BF, Girala MF, Gomez-Manero NF, Pardo FF, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999; 5:414.
11. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999; 68:155.
12. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357:587.
13. Monsour HP, Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995; 15:123.
14. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62:364.
15. McKenzie N, Keown P, Stiller C, Kostuk W, Campbell C, Keith F. Effects of cyclosporine on renal function following orthotopic heart transplantation. J Heart Transplant 1985; 4:400.
16. Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19:925.
17. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7:442.
18. Ducloux DF, Fournier VF, Bresson-Vautrin C, Rebibou JM, Billerey C, Saint-Hillier YF, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report. Transplantation 1998; 65:1504.